1. Home
  2. Upcoming Events

Driving Progress in Cardiology: Exploring the Role of FXI in Acute Coronary Syndromes & Beyond

Don’t miss our satellite symposium on the potential role of factor XI inhibition in acute coronary syndrome, Afib, and secondary stroke prevention.

Live Meeting
1.00 available credits
Information
May 1, 2025
07:05 PM - 08:35 PM ET
Walter E. Washington Convention Center
801 Mount Vernon Place Northwest, Room: 151AB (Street Level), Washington, DC, District of Columbia, United States
ReachMD Healthcare Image
ENROLL
Details
Presenters

  • Overview

    Despite significant efforts to reduce the risk of major adverse cardiovascular events (MACE) in the acute coronary syndrome (ACS) setting, as well as secondary stroke prevention and prevention of ischemic stroke in patients with atrial fibrillation, patients remain at risk. In this symposium, faculty will critically evaluate the limitations of current anticoagulation strategies, discuss factor XI inhibitors, assess the latest clinical trials and research, and consider the potential role of factor XI inhibitors in thrombosis and hemostasis. 

  • Commercial Support

    This activity is supported by an independent educational grant from Bristol Myers Squibb and Johnson & Johnson Innovative Medicine Alliance.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    C. Michael Gibson, MD, MS
    Interventional Cardiologist, Beth Israel Lahey
    Professor of Medicine, Harvard Medical School
    CEO Baim Institute for Clinical Research 
    Boston, MA

    Dr. Gibson has no relevant relationships to disclose. 

    Roxana Mehran, MD, MSCAI
    Mount Sinai Endowed Professor in Cardiovascular Clinical Research and Outcomes
    Icahn School of Medicine at Mount Sinai
    New York, NY

    Dr. Mehran has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Elixir Medical, IQVIA, Medtronic, Novo Nordisk, WebMD Global
    Stockholder: ControlRad, Elixir Medical, Stel
    Research: Abbott, Alleviant Medical, Beth Israel Deaconess Medical Center, Concept Medical, Cordis, CPC Clinical Research, Elixir Medical, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, MediaSphere Medical, Medtronic, Novartis, Protembis GmbH, RM Global BioAccess Fund Management, Sanofi US Services, Inc.

    Reviewers/Content Planners/Authors: 

    • Cindy Davidson has no relevant relationships to disclose. 
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose. 
    • Kathleen Sheridan, PhD, has no relevant relationships to disclose. 

  • Learning Objectives

    Upon completion of this activity, learners should be better able to:

    • Explain the mechanisms of action of current anticoagulant therapies, their impact on specific pathways of the coagulation cascade, and their potential to elevate the risk of serious bleeding events
    • Identify and describe the role of novel coagulation pathways, such as factor XIa inhibition, in the development of safer and more effective anticoagulant therapies
    • Assess the benefits and risks associated with emerging anticoagulant therapies, focusing on their potential to reduce bleeding complications while maintaining efficacy in thromboembolic event prevention
    • Assess the potential of factor XI as a therapeutic target to reduce thrombotic risk while minimizing bleeding complications in patients with acute coronary syndromes

  • Target Audience

    This activity has been designed to meet the educational needs of cardiologists and neurologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in care of patients requiring anticoagulant therapy to reduce their risk of MACE and stroke.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).

    The Universal Activity Number for this program is JA0006235-0000-25-048-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.

Details
Presenters
Recommended

  • Overview

    Despite significant efforts to reduce the risk of major adverse cardiovascular events (MACE) in the acute coronary syndrome (ACS) setting, as well as secondary stroke prevention and prevention of ischemic stroke in patients with atrial fibrillation, patients remain at risk. In this symposium, faculty will critically evaluate the limitations of current anticoagulation strategies, discuss factor XI inhibitors, assess the latest clinical trials and research, and consider the potential role of factor XI inhibitors in thrombosis and hemostasis. 

  • Commercial Support

    This activity is supported by an independent educational grant from Bristol Myers Squibb and Johnson & Johnson Innovative Medicine Alliance.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    C. Michael Gibson, MD, MS
    Interventional Cardiologist, Beth Israel Lahey
    Professor of Medicine, Harvard Medical School
    CEO Baim Institute for Clinical Research 
    Boston, MA

    Dr. Gibson has no relevant relationships to disclose. 

    Roxana Mehran, MD, MSCAI
    Mount Sinai Endowed Professor in Cardiovascular Clinical Research and Outcomes
    Icahn School of Medicine at Mount Sinai
    New York, NY

    Dr. Mehran has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Elixir Medical, IQVIA, Medtronic, Novo Nordisk, WebMD Global
    Stockholder: ControlRad, Elixir Medical, Stel
    Research: Abbott, Alleviant Medical, Beth Israel Deaconess Medical Center, Concept Medical, Cordis, CPC Clinical Research, Elixir Medical, Faraday Pharmaceuticals, Idorsia Pharmaceuticals, Janssen, MedAlliance, MediaSphere Medical, Medtronic, Novartis, Protembis GmbH, RM Global BioAccess Fund Management, Sanofi US Services, Inc.

    Reviewers/Content Planners/Authors: 

    • Cindy Davidson has no relevant relationships to disclose. 
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose. 
    • Kathleen Sheridan, PhD, has no relevant relationships to disclose. 

  • Learning Objectives

    Upon completion of this activity, learners should be better able to:

    • Explain the mechanisms of action of current anticoagulant therapies, their impact on specific pathways of the coagulation cascade, and their potential to elevate the risk of serious bleeding events
    • Identify and describe the role of novel coagulation pathways, such as factor XIa inhibition, in the development of safer and more effective anticoagulant therapies
    • Assess the benefits and risks associated with emerging anticoagulant therapies, focusing on their potential to reduce bleeding complications while maintaining efficacy in thromboembolic event prevention
    • Assess the potential of factor XI as a therapeutic target to reduce thrombotic risk while minimizing bleeding complications in patients with acute coronary syndromes

  • Target Audience

    This activity has been designed to meet the educational needs of cardiologists and neurologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in care of patients requiring anticoagulant therapy to reduce their risk of MACE and stroke.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).

    The Universal Activity Number for this program is JA0006235-0000-25-048-L01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)

    It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Total CME you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • ADA Statement

    Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Andrea Mathis prior to the live event at amathis@glc.healthcare.

Recommended

Program Chapters

Segment Chapters

Playlist:

Recommended

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
PrevNext